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Background: Indigenous Māori women experience a 60% higher breast cancer mortality rate compared with European
women in New Zealand. We explored the impact of differences in rates of screen detected breast cancer on inequities
in cancer stage at diagnosis and survival between Māori and NZ European women.
Methods: All primary breast cancers diagnosed in screening age women (as defined by the New Zealand National
Breast Cancer Screening Programme) during 1999–2012 in the Waikato area (n = 1846) were identified from the Waikato
Breast Cancer Register and the National Screening Database. Stage at diagnosis and survival were compared for screen
detected (n = 1106) and non-screen detected (n = 740) breast cancer by ethnicity and socioeconomic status.
Results: Indigenous Māori women were significantly more likely to be diagnosed with more advanced cancer compared
with NZ European women (OR = 1.51), and approximately a half of this difference was explained by lower rate of screen
detected cancer for Māori women. For non-screen detected cancer, Māori had significantly lower 10-year breast cancer
survival compared with NZ European (46.5% vs. 73.2%) as did most deprived compared with most affluent socioeconomic
quintiles (64.8% vs. 81.1%). No significant survival differences were observed for screen detected cancer by ethnicity or
socioeconomic deprivation.
Conclusions: The lower rate of screen detected breast cancer appears to be a key contributor towards the higher rate of
advanced cancer at diagnosis and lower breast cancer survival for Māori compared with NZ European women. Among
women with screen-detected breast cancer, Māori women do just as well as NZ European women, demonstrating the
success of breast screening for Māori women who are able to access screening. Increasing breast cancer screening rates
has the potential to improve survival for Māori women and reduce breast cancer survival inequity between Māori and
NZ European women.
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Breast cancer is the most common cancer in New
Zealand women, a rate which is the ninth highest in
the world [1]. The burden of breast cancer has an
unequal ethnic distribution in New Zealand as Indigenous
Māori women have a higher incidence and a lower
survival rate compared with NZ European women [2].* Correspondence: Sanjeewa.Seneviratne@waikatodhb.health.nz
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unless otherwise stated.Many factors are believed to be contributory to worse
breast cancer outcomes for Māori compared with NZ
European women including delay in diagnosis, inferior
quality and delays in treatment, and higher rates of
comorbidity.
In parallel with many other developed countries, New
Zealand has experienced a substantial reduction in
breast cancer mortality over the last two decades [1].
While some of the observed reduction in breast cancer
mortality in these countries has been attributed to
advances in treatment, mammographic breast cancerntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Aotearoa (BSA) is the New Zealand National Breast
Screening Programme, a free mammographic breast
screening service available for all ‘screening age’ women.
Since it was established in 1999, the BSA has provided
free biennial mammographic screening for all women
aged between 50 to 64 years and this age range was
extended to include women aged 45 to 49 and 65 to
69 years in July 2004.
Mammographic screening coverage in New Zealand
has gradually picked up over the last decade and has
achieved the target biennial coverage of 70% for NZ
European women since 2010 [4]. However, poor screening
coverage has remained a significant issue for Māori
women for whom the coverage was only 62.7% in 2012
[4], well below the 70% target coverage. Further, there was
a large variability in screening coverage rate for Māori by
region, which ranged from 54% to 79% across the country
in 2012 [5]. There is, however, close monitoring of Māori
coverage, and targets are set yearly with screening
providers to improve this. It is this effort that has
picked Māori coverage up from below 40% at the
commencement of BSA programme in 1999 to the
current level of over 60% [5]. In spite of this, lower
screening coverage remains a likely major contributor
to inequities in breast cancer burden between Māori
and NZ European women, as Māori have a higher
breast cancer incidence and are more likely to present with
advanced cancer compared with NZ European women [1].
We conducted this study to explore differences in rates of
screen detected cancer by ethnicity and socioeconomic
deprivation in a cohort of screening age women, and
to determine the contribution of these differences to
ethnic and socioeconomic inequities in breast cancer
survival in New Zealand.
Methods
Study population
Data for this study were obtained from the Waikato Breast
Cancer Registry (WBCR). The WBCR is a prospectively
maintained population based regional cancer registry that
includes in-situ and invasive breast cancers diagnosed in
the Waikato District Health Board area since 1999. The
WBCR includes over 98% of all diagnosed cancers in the
region (public and private) and validity of its data has been
reported previously [6]. The Waikato District Health Board
covers an area with a population of approximately 380,000
of whom 21% are Māori. This is the second largest regional
Māori population in New Zealand [7].
All screening age women with newly diagnosed breast
cancer between 01/01/1999 and 31/12/2012 were eligible
for this study (n = 1846). Screening age was defined
according to the BSA. This included women between
50 and 64 years up to June 2004 and women between45 and 69 years from July 2005 onwards. Screening
status was classified into screen-detected (n = 1064,
57.6%), interval (if diagnosis within 24 months from last
screening mammogram, n = 241, 13.1%) and non-interval
symptomatic (n = 541, 29.3%). Cancers diagnosed through
BSA (n = 954, 89.7%) and through opportunistic screening
mammograms arranged by physicians outside BSA (n = 110,
10.3%) were included under screen detected cancers.
Screening status for each woman diagnosed through BSA
was confirmed by comparing with screening data from the
BSA database, which include data (i.e., screen detected and
interval) for all women with breast cancer diagnosed
through the BSA programme. Details of opportunistic
screening were based on the WBCR records, and were
reconfirmed by accessing clinical and mammographic
records of all these women. For women with more than one
episode of breast cancer during the study period, only the
first cancer was included for analysis.
Study covariates
Ethnicity of each woman was obtained from the WBCR
which records self-identified ethnicity collected as a part
of the WBCR consent process. Ethnicity was categorized
in to NZ European, Māori, Pacific and Other for analysis.
Deprivation was measured using the New Zealand
Deprivation Index 2006 (NZDep2006), an area-based
measure of socioeconomic status [8]. The NZDep2006
assigns small areas of residence, a deprivation decile
on a scale of 1 to 10 based on nine socio-economic
variables measured during the 2006 population census.
Deciles were combined to create deprivation quintiles;
1–2 (least deprived), 3–4, 5–6, 7–8, and 9–10 (most
deprived). Residential status was classified as urban,
semi-urban or rural based on New Zealand Statistics
urban rural classification system [9]. Cancer stage at diag-
nosis was defined according to the Tumour, Node, and
Metastasis (TNM) staging system [10].
Outcome variables
Date and cause of death for all deceased women
(censored at 31/12/2013) were identified from the
WBCR and from the Mortality Collection of the
Ministry of Health. Follow up duration was calculated
from the date of diagnosis to the date of death, or to the
date of the last follow up when the patient was known to
be alive (censored at 31/12/2013).
Statistical analysis
Chi squared (χ2) test for trend was used to test for
univariate differences in early versus advanced stage
at diagnosis. Multivariate logistic regression analyses were
used to test for differences in early versus advanced stage
at diagnosis between Māori and NZ European women
sequentially adjusting for age, year of diagnosis, screening
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Impact of differences in screen detected cancer towards
mortality disparity between Māori and NZ European
women was explored in Cox proportional hazard models
sequentially adjusting for same covariates. Interaction terms
were included into regression models to identify possible
interactions between ethnicity, deprivation and screening
status (i.e., ethnicity*deprivation, ethnicity*screening and
deprivation*screening). We also investigated 5-year and
10-year breast cancer specific survival rates for invasive
cancers by screening status, ethnicity and socioeconomic
deprivation using Kaplan-Meier survival curves. Survival
comparisons by ethnicity were performed for Māori and
NZ European women. Pacific and Other ethnic group
women were excluded from these analyses. Statistical
analyses were performed in SPSS (Version 22).
Results
This study included a total of 1846 screening age women
(1548 invasive and 298 in-situ) with newly diagnosed
first primary breast cancer over the study period. Of
these women 1064 (57.6%) were screen detected and
782 (42.4%) were symptomatic. Of symptomatic women,
241 (30.8%) had interval and 541 (69.2%) had non-interval
symptomatic cancers. Mean follow-up was 65.5 months
(median 58 months). Sixty-seven percent of women were
followed up for a minimum of five years or until death
and 32% were followed up for ten years or until death.
Overall mean age of included women was 56.8 years
(median 56). Mean ages for in-situ and invasive breast
cancers were 56.5 (median 56.5) and 56.9 years (median
56) respectively.
Lower proportions of cancers were observed within
45–49 and 65–69 age categories as these two age categories
were included in the BSA only from July 2004 onwards
(Table 1). When women diagnosed since July 2004 were
considered alone, almost similar proportions of women
were observed to be included in each age category, which
ranged from 19.0% (55–59 age category) to 21.1% (60–64
age category).
No difference in age distribution was seen for
Māori and NZ European women where the median
age at diagnosis was 56 years. Women of higher socioeco-
nomic deprivation quintiles were significantly older at
diagnosis compared with women of lower deprivation
quintiles which ranged from a mean age of 55.2 years for
deprivation quintile 1–2 to a mean age of 57.2 years for
deprivation quintile 9–10 (p < 0.001).
Overall, 62.7% of all breast cancers among NZ European
women within screening age were screen detected
compared with 49.2% among Māori women of this
age range (p < 0.001). Of the screen detected cancers,
a higher proportion of cancers in NZ European women
were detected through opportunistic screening (10.9%)compared with Māori (7.3%), but this difference was
statistically not significant (p = 0.183). The difference
in proportion of screen detected cancer between NZ
European and Māori women was significant for inva-
sive cancers (58.3% vs. 45.1%, p = <0.001), but was
not statistically significant for in-situ cancers (85.4%
vs. 74.4%, p = 0.063).
Univariate analysis of factors associated with early
stage disease (in-situ & stage I, n = 1017) at diagnosis
compared with more advanced stage (stages II, III & IV,
n = 829) is shown in Table 1. Non-screen compared with
screen detection was significantly associated with
more advanced stage at diagnosis (OR = 5.46, p < 0.001) as
did Māori compared with NZ European ethnicity
(OR = 1.51, 95% CI 1.18-1.93, p = 0.001). No significant
differences were observed in early versus advanced stage
at diagnosis by deprivation status (p = 0.094). Table 2
shows odds ratios from multivariate logistic regression
analyses for advanced versus early stage at diagnosis in
Māori compared with NZ European women with sequential
adjustment for covariates. Adjusting for screening status
reduced the odds ratio for more advanced stage at diagnosis
in Māori compared with NZ European from 1.49
(1.15-1.91) to 1.25 (0.96-1.64). A minimal further
attenuation in odds ratio was observed with additional
adjustments for socioeconomic deprivation and residential
status (OR = 1.24, 0.95-1.65). Similarly, odds of advanced
stage at diagnosis remained largely unchanged after
introducing interaction terms into the model (OR = 1.28,
0.74-2.23). In a separate analysis (data not shown), socio-
economic deprivation was introduced into the model prior
to screening status, but made no difference to the odds
ratio (OR = 1.49, 1.16-1.93).
Next we repeated a similar regression analyses only
including invasive cancers to identify factors associated
with more advanced invasive cancer (stages II, III & IV,
n = 829) versus early invasive (stage I, n = 719) cancer
at diagnosis (data not shown). This analysis yielded results
similar to initial analysis with Māori having significantly
more advanced disease at diagnosis (unadjusted)
compared with NZ European women (OR = 1.53, 1.17-
2.01, p = 0.002). Adjusting for screening status resulted in
a reduction of age and year adjusted odds ratio for
advanced cancer in Māori compared with NZ European
from 1.52 (1.15-1.99) to 1.30 (0.97-1.75). Further adjust-
ment for deprivation made no difference to this odds ratio
(OR = 1.30, 0.96-1.75).
Table 3 shows adjusted breast cancer specific mortality
hazard ratios from Cox regression models by screening
status for women with invasive breast cancers. Maori
women were observed to have higher hazards of breast
cancer mortality overall (HR = 1.33, 0.33-3.18) and for
screen detected (HR = 1.45, 0.33-6.39) and non-screen
detected cancers (HR = 3.13, 1.58-6.18), although this
Table 1 Factors associated with early versus advanced stage at diagnosis of breast cancer by ethnicity
NZ European Māori All cancers
Characteristic (N = 1459) Earlya (N = 311) Earlya (N = 1846) Earlya
n (%) n (%) n (%) n (%) n (%) n (%) OR 95% CI p
Screening status <0.001
Screen detected 915 (62.7) 654 (71.5) 153 (49.2) 107 (69.9) 1106 (59.9) 786 (71.1) Ref
Interval 192 (13.2) 63 (32.8) 20 (6.4) 3 (15.0) 218 (11.3) 69 (31.7) 5.30 4.15-6.74
Non-screen 352 (24.1) 118 (33.5) 138 (44.4) 36 (26.1) 522 (28.3) 162 (31.0) 5.46 4.11-7.33
Age group (years)
45-49 208 (14.3) 110 (52.9) 51 (16.4) 23 (45.1) 275 (14.9) b 143 (52.0) Ref 0.005
50-54 375 (25.7) 206 (54.9) 77 (24.8) 31 (40.3) 469 (25.4) 245 (52.2) 0.99 0.74-1.33
55-59 323 (22.1) 180 (55.7) 74 (23.8) 32 (43.2) 416 (22.5) 218 (52.4) 0.98 0.73-1.33
60-64 337 (23.1) 196 (58.2) 73 (23.5) 36 (49.3) 425 (23.0) 241 (56.7) 0.83 0.61-1.12
65-69 216 (14.8) 143 (66.2) 36 (11.6) 24 (66.7) 261 (14.1) b 170 (65.1) 0.58 0.41-0.82
Deprivation
Dep 1-2 184 (12.6) 101 (54.9) 9 (2.9) 1 (11.1) 203 (11.0) 108 (53.2) Ref 0.094
Dep 3-4 157 (10.8) 104 (66.2) 23 (7.4) 13 (56.5) 186 (10.1) 120 (64.5) 0.63 0.42–0.94
Dep 5-6 339 (23.2) 189 (55.8) 62 (19.9) 29 (46.8) 411 (22.3) 223 (54.3) 0.96 0.68–1.34
Dep 7-8 492 (33.7) 279 (56.7) 95 (30.5) 43 (45.3) 614 (33.3) 338 (55.0) 0.93 0.68–1.28
Dep 9-10 287 (19.7) 162 (56.4) 122 (39.2) 60 (49.2) 432 (23.4) 228 (52.8) 1.02 0.73–1.42
Residence
Urban 783 (53.7) 435 (55.6) 150 (48.2) 75 (50.0) 990 (53.6) 539 (54.4) Ref 0.794
Semi-urban 370 (25.4) 222 (60.0) 107 (34.4) 50 (46.7) 492 (26.7) 277 (56.3) 0.93 0.75–1.15
Rural 306 (21.0) 178 (58.2) 54 (17.4) 21 (38.9) 364 (19.7) 201 (55.2) 0.97 0.76–1.23
Year of diagnosis
1999-2002 249 (17.1) 128 (51.4) 44 (14.1) 20 (45.5) 300 (16.3) 153 (51.0) Ref 0.423
2003-2006 450 (30.8) 270 (60.0) 75 (24.1) 33 (44.0) 542 (29.4) 308 (56.8) 0.79 0.60-1.05
2007-2009 363 (24.9) 203 (55.9) 86 (27.7) 45 (52.3) 479 (25.9) 263 (54.9) 0.86 0.64-1.14
2010-2012 397 (27.2) 234 (58.9) 106 (34.1) 48 (45.3) 525 (28.4) 293 (55.8) 0.82 0.62-1.09
(Characteristics of women associated with early stage [compared with advanced stage] at diagnosis of breast cancer by ethnicity for screening age women with
newly diagnosed breast cancer in the Waikato, New Zealand 1999–2012).
(aearly stage = in-situ & stage I, bonly cancers diagnosed from July 2004 onwards are included).
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cancer. Breast cancer specific mortality hazard ratios for
Māori compared with NZ European women with
sequential adjustment for covariates is shown in Table 4.
In the model for all cancers, adjusting for screening
status reduced the mortality hazard for Māori from 2.33
to 2.01, while further adjusting for deprivation resulted
in a marginal increase of hazard up to 2.09. Adjusting
for socioeconomic deprivation before adjusting for
screening (data not shown) saw a similar increase in
hazard for Māori from 2.33 to 2.37. For screen detected
cancers, Māori women had non-significant lower
hazards of mortality before (HR = 0.77) and after adjusting
for covariates (HR = 0.85), but was non-significantly higher
after introduction of interaction terms (HR = 1.45). In
contrast, for non-screen detected cancers Māori had a
significantly higher risk of mortality which was morethan double that for NZ European women before
(HR = 2.28) and after adjusting for covariates (HR = 2.37)
and introduction of interaction terms (HR = 3.13).
Unadjusted five and 10-year breast cancer specific
survival rates for invasive cancers by screening status,
ethnicity and deprivation are shown in Table 5.
Screen detected invasive cancers demonstrated the
highest five and 10-year breast cancer specific survival
rates and the lowest rates were seen for non-interval
symptomatic breast cancers. Māori women had signifi-
cantly lower crude five (90.2% vs. 77.6%) and 10-year
(83.5% vs. 73.8%) breast cancer survival rates compared
with NZ European women. Compared with women from
more affluent (1–2, 3–4 to 5–6) quintiles, women from
more deprived quintiles (7–8 and 9–10) had significantly
worse 10-year breast cancer survival rates (84.3% vs.
77.2%, p = 0.011).
Table 2 Factors associated with advanced stage at
diagnosis of breast cancer in Māori compared with NZ
European women
Characteristic OR 95% CI p
Model A (Unadjusted)) 1.51 1.18–1.93 0.001
Model B (Age adjusted) 1.49 1.16-1.91 0.002
Model C (Model B + Year of diagnosis c) 1.49 1.15-1.91 0.002
Model D (Model C + Screening status) 1.25 0.96-1.64 0.101
Model E (Model D + Deprivation) 1.24 0.94-1.64 0.133
Model F (Model E + Urban/Rural residence) 1.24 0.95-1.65 0.125
Model H (Model E + interaction terms d) 1.28 0.74-2.23 0.373
(Odds ratios for stage at diagnosis (i.e., advanced bversus early a) in Māori
compared with NZ European women with stepwise adjustment for age, year
of diagnosis, screening status, socioeconomic deprivation and urban/rural
residential status).
(aearly stage = in-situ & stage I, badvanced stage = stages I to III, cyear
categories as in Table 1, d – ethnicity x deprivation, ethnicity x screening and
deprivation x screening).
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cancer had significantly worse five and 10-year breast
cancer survival rates compared with NZ European
women (83.1% vs. 64.2% and 73.2% vs. 46.5% respectively,
p < 0.001). In contrast, for screen detected breast cancer,
Māori women had, if anything, better five and 10-year
breast cancer specific survival rates (96.9% and 94.1%)Table 3 Breast cancer specific mortality hazard ratios from Cox
All cancers
Characteristic HR 95% CI p
Ethnicity
NZ European Ref
Māori 1.33 0.33-3.18 0.964
Mode of diagnosis
Screen detected Ref











Ethnicity x Deprivation 0.65 0.31-1.36 0.253
Ethnicity x Screening 3.29 1.10-9.85 0.033
Deprivation x Screening 1.47 0.71-3.06 0.302
(x – Interaction terms).compared with NZ European women (95.8% and 90.3%),
although this was statistically non-significant (p = 0.651)
(Figure 1).
Figure 2 shows the association between screening
status and socioeconomic deprivation on 10-year
breast cancer specific survival rates based on Kaplan-Meier
survival analysis. There was a tendency for higher
survival in women from more affluent quintiles. The
difference in breast cancer specific survival rates between
more and less affluent women was substantially lower for
women with screen detected breast cancer than for
non-screen detected breast cancer. This has resulted
in a greater survival difference between screen and
non-screen detected cancer with increasing socioeconomic
deprivation.
Figure 3 illustrates breast cancer specific survivals
for women with non-screen detected cancer by socio-
economic deprivation (Dep 1–6 versus Dep 7–10) and
ethnicity. Among NZ Europeans, women of higher
socioeconomic groups (Dep 1–6) had significantly
better survival rates compared with women of lower
socioeconomic groups (Dep 7–10) (10-year survival
81% vs. 67.6%, p = 0.026). In comparison, survival rates
did not vary by deprivation status among Māori women
with non-screen detected cancer (10-year survival 51.2%
vs. 44.4%, p = 0.715).regression model (Adjusted for age and year of diagnosis)
Screen detected Non-screen detected
HR 95% CI HR 95% CI p
Ref Ref
1.45 0.33-6.39 0.620 3.13 1.58-6.18 0.001
- -
Ref 0.627 Ref 0.019
0.77 0.19-3.10 0.76 0.35-2.13
0.91 0.28-2.79 0.68 0.39-1.84
1.13 0.35-3.60 0.08 0.93-3.76
0.56 0.15-2.06 0.71 0.52-2.56
Ref 0.370 Ref 0.155
1.51 0.73-3.14 0.65 0.42-1.01
0.78 0.31-1.94 0.85 0.54-1.32
0.39 0.05-3.07 0.370 0.69 0.31-1.54 0.468
- -
- -
Table 4 Hazard ratios for breast cancer-specific mortality risk in Māori compared with NZ European women
Characteristic All cancers Screen detected Non-screen detected
HR (95% CI) p HR (95% CI) p HR (95% CI) p
Model A (Unadjusted)) 2.25 (1.62-3.12) <0.001 0.77 (0.27-2.15) 0.617 2.28 (1.59-3.26) <0.001
Model B (Age adjusted) 2.29 (1.69-3.18) <0.001 0.80 (0.29-2.25) 0.674 2.34 (1.63-3.35) <0.001
Model C (Model B + Year of diagnosisa) 2.33 (1.64-3.25) <0.001 0.84 (0.31-2.36) 0.738 2.27 (1.59-3.25) <0.001
Model D (Model C + Screening status) 2.01 (1.44-2.80) <0.001 - - - -
Model E (Model D + Deprivation) 2.09 (1.49-2.94) <0.001 0.85 (0.30-2.40) 0.762 2.39 (1.65-3.46) <0.001
Model F (Model E + Urban/Rural residence) 2.11 (1.50-2.97) <0.001 0.85 (0.30-2.41) 0.760 2.37 (1.64-3.47) <0.001
Model G (Model F + Interaction termsb) 1.33 (0.33-3.18) 0.964 1.45 (0.33-6.39) 0.620 3.13 (1.58-6.18) 0.001
(With stepwise adjustment for age, year of diagnosis, screening status, socioeconomic deprivation and urban/rural residential status).
(ayear categories as in Table 1, b – ethnicity x deprivation, ethnicity x screening and deprivation x screening.
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From this study we found that breast cancer survival
inequities between Māori and NZ European women in
the screening age group were significant for women
diagnosed through the non-screen pathway but absent
for women diagnosed through screening. Five and 10-year
survival for women diagnosed through screening were
2.8% and 5.2% higher respectively for Māori compared
with NZ European women, while Māori women diagnosed
through the non-screen pathway had a 9.9% lower 5-year
and a 17.7% lower 10-year survival than NZ European
women. We found that patterns of inequities by socioeco-
nomic deprivation were similar to those found between
Māori and NZ European women. For non-screen detected
cancer, 10-year breast cancer specific survival was 16.3%
lower for most deprived compared with women from
most affluent socioeconomic quintile.
Benefits of population based mammographic breast
cancer screening have been proven by several randomized
trials [3,11]. It has been shown that provision of biennial
screening with a 70% coverage confers an approximatelyTable 5 Breast cancer specific survival rates by screening stat
Characteristic No. of women Total breast cancer death
Screening status
Screen detected 858 40
Interval 217 36
Non-screen non-interval 473 108
Ethnicity
NZ European 1220 126
Māori 268 50
Deprivation
Dep 1-2 165 14
Dep 3-4 155 15
Dep 5-6 347 33
Dep 7-8 513 81
Dep 9-10 368 41
(Five-year and 10-year breast cancer specific survival rates by for screening age wom30% reduction in breast cancer mortality for the screening
population [12]. The breast cancer incidence for NZ
European women is similar to the rates seen in breast
cancer screening trials [12,13], but incidence in Māori
is much higher [14]. Hence, at a 70% biennial screening
rate, more Māori women may benefit than non-Māori,
and given that Māori women with symptomatic cancer
tend to present at a later stage than non-Māori, Māori
women may also have a greater reduction in breast cancer
mortality with screening. Our data lend support this
hypothesis.
Compared with NZ Europeans, a higher proportion of
breast cancer is observed among younger Māori women
due to the younger age structure of Māori population
[15]. Further, the screen detection rate for Māori women
between 45 to 49 years in initial mammographic screens
is more than twice that for non-Māori, and is 50%
greater even for subsequent screening mammograms [5].
Breast cancer in younger women tends to be more
aggressive and is more likely to be associated with
poorer outcomes [16]. Thus, it may be worthwhileus, ethnicity and socioeconomic deprivation
s 5-year survival 95% CI 10-year survival 95% CI
96.2% 94.6 - 97.8 91.8% 88.3 - 95.3
83.9% 79.3 - 88.5 73.5% 64.1 - 82.9
76.4% 70.9 - 81.9 66.3% 60.2 - 72.4
90.2% 88.2 - 92.2 83.5% 77.4 - 89.6
77.6% 71.5 - 83.7 67.8% 58.4 - 77.2
89.5 83.8 - 95.2 87.1 80.2 - 94.0
89.7 84.2 - 95.2 85.8 79.7 - 93.9
90.8 87.1 - 94.5 85.0 76.6 - 89.6
84.1 80.4 - 87.8 75.4 69.9 - 80.9
88.2 84.7 - 91.7 79.7 72.6 - 86.8
en with invasive breast cancer in the Waikato, New Zealand 1999–2012).
Figure 1 Breast cancer specific survival by ethnicity and screening status. (Kaplan-Meier survival curves for screen detected (Panel A) and
non-screen detected (Panel B) breast cancers in screening age women by ethnicity in the Waikato, New Zealand 1999–2012).
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screening for Māori women below the current screening
age limit, for instance for women between 40 and 44 years.
However, a thorough evaluation of potential benefits
versus harms of mammographic screening should be
an essential part of such an initiative.
Obese women are more likely to present with more
advanced breast cancer compared with non-obese women
and are more likely to be diagnosed through screening
mammography than non-obese [17]. Approximately 48%
of adult Māori women are obese, which is almost twice
the rate observed in NZ European women [18]. Evidence
from the USA suggests that up to 30% of later stage breast
cancer diagnosed in African American women compared
with White American women are attributable to higher
rates of obesity in African American women [19]. At
present, no New Zealand data are available on the impact
















Figure 2 Ten-year breast cancer specific survival rates by
socioeconomic deprivation. (Based on Kaplan-Meier survival curves
by socioeconomic deprivation quintile for screening age women in
the Waikato, New Zealand 1999–2012).diagnosis or outcomes. Nonetheless, higher obesity preva-
lence is likely to be another factor that would confer a
greater benefit from increased mammographic screening
coverage for Māori compared with NZ European women.
Survival differences for screen detected breast cancer
were not seen, either by ethnicity or socioeconomic
deprivation, while differences in survival were marked
and significant for non-screen detected cancer by both.
Similar observations have been reported from the UK,
the USA and the Netherlands [14,20,21]. Inequities in
breast cancer survival by ethnicity and socioeconomic
status for women diagnosed through non-screen pathway
are likely due to a range of factors. While later stage at
diagnosis for Māori and women of socioeconomically
deprived groups is the likely major factor for these
differences, higher rates of obesity, comorbidities and
differences in treatment compared with NZ European
and more affluent women, respectively are also likely
to be important. In addition, women who participate in
mammographic screening may be more likely to have
better access to health care, education, health literacy and
health seeking behaviours compared with women from
similar ethnic or socioeconomic backgrounds, who do not
participate in screening [22].
Furthermore, there is a stringent quality framework
and an audit process for the treatment of breast cancer
detected through BSA, but not for cancers diagnosed
outside BSA [4]. For instance, all women with BSA
detected breast cancers are reviewed through a multi-
disciplinary meeting, and according to BSA quality
standards, at least 90% of BSA detected women are
expected to receive their first surgical treatment within 20
working days of receiving their final diagnostic result.
Results for each regional screening provider are regularly
audited and a feedback process ensures that adequate
measures are undertaken by providers who fail to
achieve these targets. Similar audit processes or quality
frameworks are not in place for non-screen detected
Figure 3 Breast cancer specific survival by deprivation and ethnicity. (Kaplan-Meier survival curves for non-screen detected cancers in
screening age NZ European and Māori women by socioeconomic deprivation status in the Waikato, New Zealand 1999–2012).
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son for the disparities observed amongst women with
non-screen detected cancers by ethnic and socioeconomic
grouping. This is further supported by previous work
which was based on the Waikato Breast Cancer Register
on delay for primary surgical treatment of breast cancer
[23]. This study showed significantly longer delays for
Māori compared to NZ European women for non-screen
detected breast cancer, but not for cancers diagnosed
through BSA. To overcome these disparities in cancer
care, the Ministry of Health is in the process of introdu-
cing quality measures for the management of all common
cancers through the National Cancer Control Strategy.
These include the Faster Cancer Treatment Indicators
[24] and the Standards of Service Provision for Breast
Cancer Patients in New Zealand [25]. These measures will
provide benchmarks for quality cancer care and are
expected to improve care for all women with breast
cancer as well as reducing and hopefully eliminating
inequities in access, timeliness and quality of care along
the symptomatic breast cancer care pathway.
The main strengths of this study include the complete-
ness and comprehensive nature of the study sample
which include more than 98% of all breast cancers in
eligible women over the study period. Data linkage with
the national screening database enabled us to clearly
define and validate screen detected, interval and symp-
tomatic non-interval cancers. Furthermore, relatively
longer follow up has provided fairly robust survival data
with five and 10-year survival rates for groups of women
of interest. Limitations of this study include the absence
of data on previous breast cancer screening behaviours of
these women, which is a factor known to be associated
with cancer stage at diagnosis and long term outcomes
[21]. Also, we were unable to ascertain the reasons for
non-screening participation in women with symptomaticnon-interval cancer, which however is beyond the scope
of the present study. This study has used NZDep2006
as a measure of socioeconomic status, which is based
on area level deprivation [8]. Although area level
deprivation is not as accurate as individually measured
socioeconomic status, NZDep2006 has been validated as
an accurate proxy measure for assessment of individual
deprivation [26].Conclusions
We have observed a significantly higher rate of advanced
stage breast cancers among screening age Māori compared
with NZ European women, of which approximately a half
was explained by lower rate of screen detected cancer
among Māori women. Significant differences in breast
cancer survival by ethnicity and socioeconomic deprivation
were observed for non-screen detected, but not for
screen detected breast cancer. Māori women who do
have screen detected breast cancers appear to do just
as well as NZ European women demonstrating the
success of BSA for Māori women who are able to access
this programme. Achieving at least the national 70%
biennial breast cancer screening rate for eligible Māori
women will likely make a significant contribution to redu-
cing cancer deaths for Māori as well as reducing inequities
in cancer deaths between Māori and NZ European women
in New Zealand.
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